We offer a comprehensive neuroimmunology product line comprised of robust assays for simple, esoteric testing for important neuroimmune markers and it is supported by numerous publications.
BÜHLMANN GanglioCombi® MAG ELISA – intended to detect autoantibodies against defined relevant neural antigens/epitopes in human serum samples.
Health Canada License: 100476 US: Research Use Only. Not for diagnostic procedures.
Anti-MAG Autoantibodies ELISA – intended for the quantitative determination of human IgM-auto-antibodies directed against Myelin Associated Glycoprotein (MAG) in serum.
Health Canada License: 89118 US: Research Use Only. Not for diagnostic procedures.
Anti-SGPG Autoantibodies ELISA – intended for the semi-quantitative determination of human IgM-auto-antibodies directed against sulfate-3-glucuronyl paragloboside [SGPG] and sulfate-3-glucuronyllactosaminyl-paragloboside [SGLPG].
Health Canada License: 89117 US: Research Use Only. Not for diagnostic procedures.
BÜHLMANN GanglioCombi™ Light ELISA– intended to detect antibodies against defined relevant neural antigens GM1, GD1b and GQ1b (IgG and IgM) in serum samples.
Health Canada License: 100436 US: Research Use Only. Not for diagnostic procedures.
Anti-GM1 Autoantibodies ELISA– designed for the quantitative determination of IgG and/or IgM autoantibody
isotypes directed against GM1 in human serum using individual IgG- and IgM-conjugates
Health Canada License: 89116 US: Research Use Only. Not for diagnostic procedures.
Comprehensive assay for anti-MAG and most prevalent anti-Ganglioside antibodies: (GM1, GM2, GD1a, GD1b, and GQ1b).
The Neuroimmunology product line by BÜHLMANN is a list of robust assays for simple, esoteric testing for important neuroimmune markers and it is supported by numerous clinical publications. The BÜHLMANN GanglioCombi® MAG ELISA is one of the top assays in this Neuroimmunology line providing a means to effectively measure anti-Ganglioside and anti-MAG antibodies. This ELISA is based on synthetic “MAG” antigen and offers high specificity, accuracy and sensitivity.
BÜHLMANN GanglioCombi® MAG ELISA is an incredible tool for researchers, providing a more valuable, simple, cost-effective alternative to existing methods.
Why Measure anti-Ganglioside and anti-MAG Antibodies?
Measuring anti-Ganglioside and anti-MAG antibodies allows for a targeted tool to study the most prominent immune-mediated neuropathies. This ELISA is the only assay in the market that offers this testing in ELISA format as well as the only test that combines gangliosides and MAG in one assay.
Key Advantages of BÜHLMANN GanglioCombi® MAG ELISA
- Specific: Utilizes synthetic “MAG” antigen
- Most Sensitive: Most Sensitive Assay in the market in comparison to other techniques
- Fast Results: Results in 4.5 hours
- Excellent Agreement with Gold Standard Assay: Agreement between “MAG” and the gold standard anti-MAG ELISA
- Simple, Cost Effective, Flexible: Ease of use with ELISA method and ability to measure multiple antibodies
Vice President, Business Development
Collin joined BDC in 2015 as the VP of Business Development. He has a MS in Cell Physiology, has been studying biomarkers in the medical diagnostics industry for 10+ years and has worked and published in the area of Diabetes, IBD, Cystic Fibrosis and neural pathobiology.
Technical Sales Specialist
Jennifer joined BDC as a Technical Sales Specialist in 2016, having spent 17 years performing Clinical Microbiology and Molecular Diagnostics in various hospital laboratory settings including MA General Hospital and Southern New Hampshire Medical Center. She is ASCP certified and received her BS in Medical Technology at the University of New Hampshire.
Product Manager, Neuroimmunology
Renato obtained his MS degree in Biology from the University of Basel (Switzerland), where he completed the studies with a special focus in Parasitology and Neurobiology. He joined BÜHLMANN in 1997 after some years in research in these fields in Switzerland and abroad. Renato initially worked in Product Support and later became Product Manager for the Neuroimmunology products in 2008 and has gained extensive expertise in neural biomarkers specifically of the peripheral nervous system.